【摘要】 目的检测大肠癌患者根治术中植入氟尿嘧啶植入剂后外周血survivin、caspase-3、CD44V6的变化,探讨其对肿瘤微转移及预后的影响。方法 64例大肠癌患者(Dukes B期、C期)随机分为治疗组和对照组,每组32例。2组均行标准根治术,治疗组术中植入氟尿嘧啶植入剂;对照组术中未应用此药。采用RT-PCR方法测定手术前后外周血中survivin、caspase-3表达水平,流式细胞术检测CD44V6含量。结果术前2组survivin、caspase-3、CD44V6的水平差异无统计学意义(P>0.05);术后14 d,治疗组survivin水平(0.362±0.183)低于对照组(0.585±0.207),caspase-3水平(2.001±0.146)高于对照组(1.654±0.111);术后CD44V6水平治疗组(1.857±0.535)和对照组(3.471±0.496)明显低于术前的(9.557±1.170)和(9.729±0.943),且治疗组CD44V6水平低于对照组(均P<0.05)。结论术中植入氟尿嘧啶植入剂,对大肠癌的微转移及预后有重要意义,有望提高大肠癌术后的远期疗效。更多还原

【Abstract】 Objectives To observe the pre and post-operational changes of the expressions of survivin, caspase-3 and CD44V6 in patients with colorectal cancer after intra-abdominal implantation of sustained releasing fluorouracil. Methods Sixty-four patients with colorectal cancer(Dukes’ stage of B and C) were divided into treatment group and control group, 32 patients in each group. The standard radical surgery was performed in two groups of patients. The fluorouracil implants were implanted intra-abdominally in treatment group. The peripheral blood levels of surviving and caspase-3 were detected by RT-PCR. The level of CD44V6 was detected by flow cytometry in two groups of patients. Results There were no significant differences in levels of survivin, caspase-3 and CD44V6 before surgery between two groups(P>0.05). The level of survivin(0.362±0.183) was significantly lower at 14 days after operation in treatment group than that of control group(0.585±0.207), but the level of caspase-3(2.001±0.146) was significantly higher than that of control group(1.654±0.111). The levels of CD44V6 were significantly lower in treatment group(1.857±0.535) and control group(3.471±0.496) after operation than those before operation(9.557±1.170 and 9.729±0.943, P<0.05), and the level of CD44V6 was significantly lower in treatment group than that of control group(P<0.05). Conclusion The implant for the sustained release of fluorouracil showed a positive impact on micrometastases and prognosis of colorectal cancer, while improved the long-term efficacy of postoperative colorectal cancer.更多还原